NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it is working with the new Luxembourg Clinical Proteomics unit of the Public Research Centre for Health (CRP-Santé) on developing workflows that overcome current bottlenecks in biomarker discovery and assay development for clinical proteomics research.
The firm said that it will collaborate with Bruno Domon, who is the director of the new institute. Thermo Fisher said that it has collaborated with Domon since 2007, and such collaboration led to the development of the intelligent Selected Reaction Monitoring (iSRM) technology now incorporated within the Thermo Scientific TSQ family of triple quadrupole mass spectrometers.
Domon's CRP-Santé research group will use the recently introduced Thermo Scientific LTQ Orbitrap Velos hybrid mass spectrometer equipped with electron transfer dissociation (ETD) for its biomarker discovery efforts. Thermo Fisher said that the new instrument is more accurate, faster and more sensitive than older generation LTQ Orbitrap instruments.
"This collaboration provides a unique opportunity for the company to expand its role in the development of cutting-edge biomarker research tools and consolidate its presence within the EU," Ian Jardine, VP of global R&D for Thermo Fisher Scientific, said in a statement.